Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

141.33 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 30
Open 141.33
Bid (Size) 130.05 (1)
Ask (Size) 143.00 (1)
Prev. Close 141.33
Today's Range 141.33 - 141.33
52wk Range 84.23 - 154.61
Shares Outstanding 99,000,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Demystifying Neurocrine Biosciences: Insights From 12 Analyst Reviews
 
Via Benzinga
Neurocrine Biosciences Inc (NASDAQ:NBIX) Presents an Affordable Growth Opportunity
Discover Neurocrine Biosciences (NBIX), an affordable growth stock with strong financials, solid profit margins, and a promising pipeline in neuroscience treatments. 
Via Chartmill

Performance

YTD
+2.5%
+2.5%
1 Month
-3.6%
-3.6%
3 Month
+7.2%
+7.2%
6 Month
+40.4%
+40.4%
1 Year
+21.2%
+21.2%

More News

Read More
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Presents a Compelling Growth and Breakout Opportunity
Via Chartmill
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Neurocrine Biosciences Inc (NASDAQ:NBIX): An Affordable Growth Candidate in Biotechnology
Via Chartmill
Earnings Scheduled For July 30, 2025
Via Benzinga
Analyst Expectations For Neurocrine Biosciences's Future
Via Benzinga
Where Neurocrine Biosciences Stands With Analysts
Via Benzinga
Neurocrine Biosciences Inc (NASDAQ:NBIX) Screened as a Strong Growth Stock with Bullish Technical Setup
Via Chartmill
Breaking Down Neurocrine Biosciences: 12 Analysts Share Their Views
Via Benzinga
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Prime GARP Candidate with Strong Growth and Reasonable Valuation
Via Chartmill
Neurocrine (NBIX) Q2 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Neurocrine (NBIX) Q2 Revenue Jumps 17%
Via The Motley Fool
The Analyst Verdict: Neurocrine Biosciences In The Eyes Of 17 Experts
Via Benzinga
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Strong Affordable Growth Pick with Solid Fundamentals
Via Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX) Beats Q2 2025 Earnings Estimates but Stock Drops 8.6% on Investor Concerns
Via Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX) Emerges as a Strong Growth Stock with Breakout Potential
Via Chartmill
Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity
Via Investor's Business Daily
Topics Intellectual Property
A Glimpse Into The Expert Outlook On Neurocrine Biosciences Through 14 Analysts
Via Benzinga
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - A Strong Growth Stock with Reasonable Valuation
Via Chartmill
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) – A Strong Growth Stock with Technical Breakout Potential
Via Chartmill
3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking
Via MarketBeat
Topics Artificial Intelligence Economy
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - A Promising Affordable Growth Stock
Via Chartmill
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) – A Strong Growth Stock with Technical Breakout Potential
Via Chartmill
Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors
From Fate Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Neurocrine Biosciences, Inc. - Common Stock publicly traded?
Yes, Neurocrine Biosciences, Inc. - Common Stock is publicly traded.
What exchange does Neurocrine Biosciences, Inc. - Common Stock trade on?
Neurocrine Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Neurocrine Biosciences, Inc. - Common Stock?
The ticker symbol for Neurocrine Biosciences, Inc. - Common Stock is NBIX on the Nasdaq Stock Market
What is the current price of Neurocrine Biosciences, Inc. - Common Stock?
The current price of Neurocrine Biosciences, Inc. - Common Stock is 141.33
When was Neurocrine Biosciences, Inc. - Common Stock last traded?
The last trade of Neurocrine Biosciences, Inc. - Common Stock was at 10/20/25 04:00 PM ET
What is the market capitalization of Neurocrine Biosciences, Inc. - Common Stock?
The market capitalization of Neurocrine Biosciences, Inc. - Common Stock is 13.99B
How many shares of Neurocrine Biosciences, Inc. - Common Stock are outstanding?
Neurocrine Biosciences, Inc. - Common Stock has 14B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.